Bronchodilators Market Highlights

According to MRFR analysis,Bronchodilators Market insights report expects the industry size to register a CAGR of 4.90% during the forecast period of 2022 to 2030 and is expected to reach USD 31836.16 Million by 2030.

Bronchodilators are medications that make breathing easier by opening the airways of the lung by relaxing bronchial muscles. They are used to treat various respiratory problems such as asthma, COPD, and other allergic reactions that cause breathing problems.

The growth of the global bronchodilators market is driven by various factors such as increase in prevalence of pulmonary disorders, increasing geriatric population and increasing mergers and acquisitions by prominent players in the market. However, side effects associated with bronchodilators and government regulations related to the safety efficacy of the bronchodilators are projected to hamper the growth of the global bronchodilators market.

The global bronchodilators market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Segmentation

The global bronchodilators market has been segmented based on drug type, disease, mode of action, and route of administration.

The market, based on drug type, has been divided into adrenergic drugs, anticholinergics, a phosphodiesterase inhibitor, and combination drugs.

The adrenergic segment is likely to be the largest during the review period as they are the most potent bronchodilators approved for clinical use in asthma and obstructive lung disease. The combination drugs segment is predicted to be the fastest-growing segment. These combination drugs are used if COPD and asthma are not controlled with monotherapy. These combinations involving two long-acting bronchodilators with differing modes of action.

The global bronchodilators market has been segmented, on the basis of disease, intoasthma, COPD, and others. The asthma segment is expected to hold the majority share of the market, owing to the rise in patients affected with asthma. The COPD segment is expected to be the fastest-growing as bronchodilators are primary treatment for chronic obstructive pulmonary disease (COPD) as they help to alleviate bronchial obstruction and airflow limitation.

In terms of mode of action, the global bronchodilators market has been segmented into short-acting bronchodilators and long-acting bronchodilators. Short-acting bronchodilators are expected to be the largest segment, owing to its ability to provide quick relief from sudden, unexpected attacks of breathlessness.

Theroute of administrationof the market is oral and parenteral. The oral route of administration segment is expected to hold the largest share of the market due to the advantages such as ease and simplicity of administration along with control of delivered dose.

Key Players

Some of the key players mentioned in the Bronchodilators Market outlook report are GlaxoSmithKline (UK), Novartis AG (Switzerland), Merck Co., Inc. (US), Abbott Laboratories (US), Boehringer Ingelheim GmbH (Germany), AstraZeneca plc (UK), F. Hoffmann LA-Roche AG (Switzerland), Teva Pharmaceutical (Israel) and Pfizer Inc. (US) among others.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East Africa. The Americas are expected to be the largest market owing to the rising per capita healthcare expenditure. The bronchodilators market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European bronchodilators market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The bronchodilators market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of respiratory disorders and the increasing pool of patient population, the market in Asia-Pacific is expected to be the fastest-growing. The bronchodilators market in the Middle East Africa has been divided into the Middle East and Africa.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: [email protected]

Website: https://www.marketresearchfuture.com